Say Goodbye to Methotrexate in PMR? Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24 https://t.co/Q5Sw9dvYqJ https://t.co/jvEmg6aPcq